Cardiotoxicity of AntitumorousTreatment
Authors:
J. Horáček 1,2; R. Pudil 2; M. Tichý 1,2; L. Jebavý 1,2; L. Slováček 1,2
Authors‘ workplace:
Katedra válečného vnitřního lékařství Vojenské lékařské akademie J. E. Purkyně, Hradec Králové 2II. interní klinika Fakultní nemocnice, Hradec Králové
1
Published in:
Transfuze Hematol. dnes,, 2004, No. 2, p. 62-69.
Category:
Overview
Cardiotoxicity is a serious and relatively frequent complication in patients treated for cancer. Antitumoroustreatment can cause a number of undesirable cardiac side effects, such as arrhythmias,myocardial ischaemia, sudden death and heart failure. Cardiotoxicity can manifest anytime duringtreatment and anytime after its termination. Late cardiotoxicity of anthracyclines, which can manifestas chronic heart failure more than one year after termination of the treatment, is one of the most seriousproblems. In viewof indisputable success of antitumorous treatment recently, the issue of cardiotoxicitybecomes more and more relevant. The authors review the most frequent cardiac complications ofantitumorous treatment. They emphasize the cardiotoxicity of anthracyclines and its derivatives,because they represent the greatest risk.Furthermore, they reviewthe cardiotoxity of other cytostatics,immunomodulators, radiotherapy and cardiac complications associated with transplantation of haematopoieticcells.
Key words:
cardiotoxicity, cytostatics, immunomodulators, radiotherapy, transplantation of haematopoieticcells
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2004 Issue 2
Most read in this issue
- Translocation of t(14;18) and its importance infollow up of minimal residual disease in follicular lymphoma
- Four-year retrospective study of autoimmunehemolytic anemia in children in the Czech Republic
- Quantitative analysis of chimerism after allogenichematopoietic cells transplantation
- Cardiotoxicity of AntitumorousTreatment